Related Experiment Video
Updated: Jun 26, 2026
04:48
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
[Pathophysiology of chemotherapy-associated thrombosis]
1Abteilung für Hämatologie und Hämostaseologie, Universitätsklinik für Innere Medizin I, Medizinische Universität Wien, Osterreich. daniel.lechner@meduniwien.ac.at
Hamostaseologie
|January 20, 2009
Summary
Cancer treatments like chemotherapy increase the risk of blood clots (thromboembolism) in patients. Newer therapies, including angiogenesis inhibitors, may also contribute to this risk, requiring further research into the underlying causes.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Context:
- Cancer patients undergoing antineoplastic therapy face an elevated risk of thromboembolic events.
- Thromboembolism, encompassing both venous and arterial clots, is a significant concern in oncology.
- Emerging cancer treatments introduce new complexities to understanding thrombosis risk.
Purpose:
- To review current clinical and pathophysiological data on chemotherapy-associated thromboembolism.
- To examine the impact of novel therapeutic strategies, such as angiogenesis inhibitors and immunomodulatory agents, on thrombosis.
- To highlight the gaps in knowledge regarding the pathogenesis of treatment-related thrombosis.
Summary:
- Epidemiological data confirm that antineoplastic agents and regimens significantly increase the risk of venous and arterial thromboembolism in cancer patients.
- This review focuses on the clinical and pathophysiological aspects of chemotherapy-associated thrombosis, with particular attention to newer agents like angiogenesis inhibitors and immunomodulatory drugs.
- Despite extensive research, a complete understanding of the mechanisms driving chemotherapy-associated thrombosis remains elusive.
Impact:
- Informs clinicians about the prothrombotic risks associated with various cancer therapies.
- Guides the development of future research into the pathophysiology of cancer-associated thrombosis.
- Highlights the need for improved risk stratification and management strategies for thromboembolism in cancer patients.
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...